Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 12/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804665 | 0.93 | FFAR1 (0.42) | FFAR1FFAR4THRBPTGER4PTGER3 | |
| SCHEMBL19804679 | 0.91 | FFAR1 (0.41) | FFAR1FFAR4THRBPTGER4PTGER3 | |
| SCHEMBL19804572 | 0.87 | FFAR4 (0.39) | FFAR1FFAR4THRBNPC1RAB9A | |
| SCHEMBL19796893 | 0.86 | THRB (0.51) | THRB | |
| SCHEMBL19804794 | 0.86 | PDE1A (0.38) | FFAR1FFAR4THRBPTGER4PTGER3 | |
| SCHEMBL19804623 | 0.85 | FFAR4 (0.43) | FFAR1FFAR4THRB | |
| SCHEMBL19804666 | 0.85 | THRB (0.51) | FFAR1FFAR4THRBPTGER4PTGER3 | |
| SCHEMBL19624565 | 0.84 | FFAR4 (0.44) | FFAR1FFAR4THRB | |
| SCHEMBL19804663 | 0.84 | FFAR1 (0.41) | FFAR1FFAR4PTGER4PTGER3 | |
| SCHEMBL19804484 | 0.84 | CYP4F2 (0.37) | FFAR1FFAR4THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | FFAR1 1057/4885FFAR4 1715/4885THRB 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.